The $1.5 billion weight-loss market gets a new player

A major trial suggests that a new weight-loss jab, known as the 'Godzilla jab', could help tackle multiple serious conditions linked to obesity, including arthritis, heart disease, and sleep apnoea.. The treatment, callled retatrutide, helped 45 per cent of patients lose at least 30 per cent of their body weight, with some achieving results close to those seen with bariatric surgery.

According to the American Diabetes Association's 2026 Scientific Sessions, the trial involved more than 2,300 participants and showed that patients lost up to around 30 per cent of their body weight - roughly 70lbs (32kg) on average over the course of the study.

Currently, the most powerful licensed weight-loss jab, Mounjaro, helps users lose around 20.9 per cent of their body weight over 72 weeks.

Retatrutide: a triple-agonist with a twist

Retatrutide works as a triple-agonist, targeting three hormone receptors linked to appetite, metabolism, and energy burn. While earlier weight-loss jabs have largely focused on suppressing appetite, this drug also boosts the body's calorie-burning processes, helping explain its wider health effects.

Experts warn that the treatment is still experimental, with common side effects including naausea, diarrhoea, and vomiting, and more research is needed to confirm its long-term safety.

The rapid expansion of the market for this treatment is a concern

The rapid expansion of the market for this treatment is also a concern, with social media influencers and online forums playing a significant role in promoting the use of retatrutide, despite its lack of approval and potential risks.

As the market for weight-loss treatments continues to grow, it's essential to prioritize caution and ensure that any new treatments are thoroughly tesetd and proven safe before they reach the public .